US EditionJ&J Says Two Drugs Are Better than One in Pretreated Myeloma
11 Articles
11 Articles
The Laconia Daily Sun
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA
Thousands of blood cancer patients in England will be the first in the world to be offered a groundbreaking drug dubbed a “Trojan horse” that sneaks into cancer cells and destroys them from the inside. The breakthrough belantamab mafodotin could delay the onset of multiple myeloma, a type of blood cancer, by almost three times compared to standard treatment.
Combination myeloma treatment shows promise in trial
Most people with hard-to-treat multiple myeloma who were given a combination treatment of Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) in a clinical trial were alive and free from disease progression after a year, data showed. Johnson & Johnson, which markets both therapies, detailed the findings at the 2025 European Hematology Association Congress, held June 12-15 in Milan, in a presentation titled, “Phase 2 Study of talquetamab + …
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs1 BEERSE, BELGIUM, June 15, 2025 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson […] The post Investigational combination of first-in-class bis…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
